{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:28:13Z","timestamp":1793939293107,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC240417"],"award-info":[{"award-number":["20252BAC240417"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009102","name":"Education Department of Jiangxi Province","doi-asserted-by":"publisher","award":["GJJ2203530"],"award-info":[{"award-number":["GJJ2203530"]}],"id":[{"id":"10.13039\/501100009102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.trsl.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:42:16Z","timestamp":1789573336000},"page":"57-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The AR\/ARD1\/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer"],"prefix":"10.1016","volume":"298","author":[{"given":"Chongwu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0002","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"npj Breast Cancer."},{"key":"10.1016\/j.trsl.2026.09.011_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116584","article-title":"Therapeutic vulnerabilities in triple negative breast cancer: stem-like traits explored within molecular classification","volume":"174","author":"Huang","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-022-01574-4","article-title":"Androgen receptor function and targeted therapeutics across breast cancer subtypes","volume":"24","author":"Kolyvas","year":"2022","journal-title":"Breast Cancer Research"},{"issue":"2\u20134","key":"10.1016\/j.trsl.2026.09.011_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.currproblcancer.2016.09.004","article-title":"Targeting the androgen receptor in triple-negative breast cancer","volume":"40","author":"Gucalp","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.trsl.2026.09.011_bib0006","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.06008","article-title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling","volume":"6","author":"Claessens","year":"2008","journal-title":"Nucl Recept Signal"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0007","first-page":"3","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin Biochem Rev."},{"issue":"21","key":"10.1016\/j.trsl.2026.09.011_bib0008","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.trsl.2026.09.011_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/j.trsl.2026.09.011_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cancers9030021","article-title":"AR signaling in breast cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.trsl.2026.09.011_bib0011","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fendo.2018.00594","article-title":"The divergent function of androgen receptor in breast cancer; analysis of steroid mediators and tumor intracrinology","volume":"9","author":"Bleach","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.trsl.2026.09.011_bib0012","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/1078-0432.CCR-13-0583","article-title":"New strategies for triple-negative breast cancer\u2013deciphering the heterogeneity","volume":"20","author":"Mayer","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.trsl.2026.09.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279746","article-title":"The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics","volume":"17","author":"Tahtamouni","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.trsl.2026.09.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105791","article-title":"Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer","volume":"206","author":"Wang","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"19","key":"10.1016\/j.trsl.2026.09.011_bib0015","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"9","key":"10.1016\/j.trsl.2026.09.011_bib0016","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2026.09.011_bib0017","series-title":"Nuclear Receptors in Human Health and Disease","first-page":"277","article-title":"Epigenetic coregulation of androgen receptor signaling","volume":"1390","author":"Fernandes","year":"2022"},{"issue":"2","key":"10.1016\/j.trsl.2026.09.011_bib0018","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cells13020191","article-title":"Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications","volume":"13","author":"Lumahan","year":"2024","journal-title":"Cells"},{"issue":"27","key":"10.1016\/j.trsl.2026.09.011_bib0019","doi-asserted-by":"crossref","first-page":"20853","DOI":"10.1074\/jbc.M000660200","article-title":"p300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation*","volume":"275","author":"Fu","year":"2000","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.trsl.2026.09.011_bib0020","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1101\/gad.12.11.1638","article-title":"The histone acetylase PCAF is a nuclear receptor coactivator","volume":"12","author":"Blanco","year":"1998","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0021","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41467-025-55960-5","article-title":"Illuminating the impact of N-terminal acetylation: from protein to physiology","volume":"16","author":"McTiernan","year":"2025","journal-title":"Nature Communications"},{"issue":"21","key":"10.1016\/j.trsl.2026.09.011_bib0022","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.3390\/ijms21218010","article-title":"NAA10 as a new prognostic marker for cancer progression","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"7","key":"10.1016\/j.trsl.2026.09.011_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0100-7","article-title":"Versatility of ARD1\/NAA10-mediated protein lysine acetylation","volume":"50","author":"Vo","year":"2018","journal-title":"Exp Mol Med"},{"issue":"7","key":"10.1016\/j.trsl.2026.09.011_bib0024","first-page":"1","article-title":"ARD1\/NAA10 in hepatocellular carcinoma: pathways and clinical implications","volume":"50","author":"Lee","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.trsl.2026.09.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121217","article-title":"ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer progression","volume":"313","author":"Fang","year":"2023","journal-title":"Life Sciences"},{"issue":"5","key":"10.1016\/j.trsl.2026.09.011_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"The Oncologist"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0027","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/bcr733","article-title":"Expression of androgen receptor and prostate-specific antigen in male breast carcinoma","volume":"6","author":"Kidwai","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.trsl.2026.09.011_bib0028","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","article-title":"Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype","volume":"68","author":"Gerratana","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.trsl.2026.09.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108428","article-title":"Androgen receptor-induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p\/CCR5 axis","volume":"301","author":"Hu","year":"2025","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.trsl.2026.09.011_bib0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CM9.0000000000002930","article-title":"Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer","volume":"137","author":"Xu","year":"2024","journal-title":"Chin Med J"},{"issue":"3","key":"10.1016\/j.trsl.2026.09.011_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/molecules25030588","article-title":"Characterization of lysine acetyltransferase activity of recombinant Human ARD1\/NAA10","volume":"25","author":"Vo","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.trsl.2026.09.011_bib0032","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/MCB.22.10.3373-3388.2002","article-title":"Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function","volume":"22","author":"Fu","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.trsl.2026.09.011_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/febs.16695","article-title":"Acetylation of nuclear receptors in health and disease: an update","volume":"291","author":"Ashton","year":"2024","journal-title":"FEBS J."},{"issue":"21","key":"10.1016\/j.trsl.2026.09.011_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115819","article-title":"DLGAP5 Regulates the proliferation, migration, invasion, and cell cycle of breast cancer cells via the JAK2\/STAT3 signaling axis","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12967-024-04910-8","article-title":"DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.trsl.2026.09.011_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/9292536","article-title":"High expression of DLGAP5 indicates poor prognosis and immunotherapy in lung adenocarcinoma and promotes proliferation through regulation of the cell cycle","volume":"2023","author":"Tang","year":"2023","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0037","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.trsl.2026.09.011_bib0038","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"11","key":"10.1016\/j.trsl.2026.09.011_bib0039","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.trsl.2026.09.011_bib0040","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC oncogene is a global regulator of the immune response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trsl.2026.09.011_bib0041","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.trsl.2026.09.011_bib0042","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","article-title":"A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo","volume":"22","author":"Zhao","year":"2020","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.trsl.2026.09.011_bib0043","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol Cancer Ther"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:10:03Z","timestamp":1793938203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426001970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"alternative-id":["S1931524426001970"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.09.011","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The AR\/ARD1\/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}